Characterization of Oral Gut-Selective vs. Systemic JAK Inhibitors in the Mouse Oxazolone Colitis Model

Influenza A virus (IAV) utilizes a multivalent binding strategy to the host cell, binding its trimeric spike protein hemagglutinin (HA) to sialic acid present on the cellular membrane.

In November of 2019, the City and County of San Diego officially proclaimed “mRNA Day” to honor the grand opening of the TriLink BioTechnologies facility and Maravai LifeSciences headquarters. We’re carrying the torch forward to establish a tradition of celebrating mRNA by bringing together leaders in the industry to share their scientific knowledge, research expertise, and predictions for the future.

Genome-scale CRISPR screens in cancer cell lines have enabled the unprecedented identification of genome-scale vulnerabilities and co-dependencies. However, a significant obstacle in identifying co-dependencies is that the range of genomic features defines the discovery space. Therefore, it is clear that paired perturbations are needed to comprehensively map co-dependencies and establish functional genetic interaction maps.

Enabling formulations becomes more and more necessary to obtain adequate exposure of APIs during (pre)-clinical research. Currently, most registered formulations to improve bioavailability are based on lipidic systems, which make use of intrinsic digestion processes within the GI tract, facilitating the absorption of APIs. Aside from a general absorption mechanism, lipidic systems can also promote lymphatic transport of poorly soluble drugs, such as hormones. In addition, many different indications, such as HIV therapy, oncology, immunosuppressant and even arising therapies related to medicinal cannabis (e.g. CBD) can benefit from lipid formulations. These formulations create multiple possibilities for oral administration because they can be manufactured as solutions, suspensions, emulsions, and self-(micro)emulsifying systems.